Mavacamten
As of the edition of 20 October 2026, Mavacamten is a small molecule: marketed, first approved in 2022 (US); acts on MYH7; US protection ends in 2036.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2025
- Kind
- Small molecule
- Brand name
- Camzyos
- First approved
- 28 April 2022 (US)
- Approvals on record
- 11 in 5 regions
- Holder of the most recent approval
- Bristol Myers Squibb
- Registered trials
- 41, 1 stopped early
- Disease areas
- Heart and blood vessels; Infections
US protection
US protection ends in 2036.
The last listed US drug-substance patent ends in 2036. The application that gives this date is held by Bristol Myers Squibb.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product16 listings count towards this date. The exact date and each listing are in the product.
See the exact date and the 16 listings behind itRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| MYH7 | Myosin-7 | P12883 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 18 | 4 | 14 | 0 |
| Phase 1 | 8 | 8 | 0 | 0 |
| Phase 2 | 4 | 4 | 0 | 0 |
| Phase 3 | 7 | 5 | 1 | 1 |
| Phase 4 | 4 | 0 | 4 | 0 |
| All trials | 41 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Bristol Myers Squibb | Originator, Applicant and Lead sponsor of trials | 2014 to now |